new formulations of Actonel and Fosamax and a new bisphosphonate called Reclast
June 2007
View the FDA's preliminary statement concerning bisphosphonates and atrial fibrillation
Drug companies will promote new formulations of Actonel and Fosamax and a new bisphosphonate called Reclast.
It's a competitive market. There are a huge number of potential patients...and big money is at stake.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote